Medical Pharmacology: Chapter 40 — Immunopharmacology -- Module 5 — Complement Pharmacology, IVIG, and Emerging Immunological Targets

Chapter 40 — Immunopharmacology — Module 5 — Complement Pharmacology, IVIG, and Emerging Immunological Targets

1. A 26-year-old woman with PNH (paroxysmal nocturnal hemoglobinuria) has been on eculizumab for 18 months. She received meningococcal ACWY conjugate and MenB vaccines before starting therapy and was prescribed prophylactic penicillin V 250 mg twice daily. She ran out of penicillin three weeks ago and has not refilled the prescription. She presents to the emergency department with sudden onset of severe headache, fever of 40.1°C, neck stiffness, non-blanching petechial rash spreading across her trunk and lower extremities, and confusion that developed over the past four hours. Blood pressure is 88/52 mmHg. Which of the following is the most appropriate immediate next step?

A) Obtain a lumbar puncture immediately for CSF (cerebrospinal fluid) analysis to confirm bacterial meningitis before initiating antibiotics, as empiric treatment without microbiological diagnosis may mask the causative organism and complicate subsequent antibiotic selection in this immunologically complex patient.
B) Administer a booster dose of meningococcal MenB vaccine and begin oral amoxicillin; the combination of vaccine re-stimulation and antibiotic prophylaxis will address the likely early meningococcal colonization before invasive disease is fully established, while preserving the ability to obtain diagnostic cultures.
C) Discontinue eculizumab immediately and administer fresh frozen plasma to restore complement function; recovery of terminal complement activity will assist in clearing Neisseria meningitidis before antibiotics are initiated, reducing the risk of endotoxin-mediated shock from rapid bacterial lysis.
D) Administer intravenous ceftriaxone immediately without waiting for lumbar puncture or culture results; eculizumab abolishes MAC (membrane attack complex) formation — the primary bactericidal defense against Neisseria meningitidis — and this presentation is consistent with fulminant meningococcal sepsis, a life-threatening emergency in complement-inhibited patients that requires empiric antibiotic therapy within minutes.
E) Administer IVIG at 1 g/kg intravenously to provide pooled donor bactericidal anti-meningococcal antibodies while blood cultures are pending; the opsonophagocytic antibodies in IVIG will compensate for absent MAC-mediated lysis and provide an adequate bridge until culture-directed therapy is initiated.

ANSWER: D

Rationale:

This vignette presents fulminant meningococcal sepsis in a patient on eculizumab — one of the most time-critical emergencies in complement inhibitor pharmacology. Eculizumab prevents C5 cleavage and completely abolishes MAC formation; the MAC is the principal bactericidal mechanism against Neisseria meningitidis, and patients on eculizumab are pharmacologically equivalent to individuals with inherited terminal complement deficiency in terms of meningococcal vulnerability. The clinical picture — sudden onset of severe headache, high fever, meningismus, non-blanching petechial rash, confusion, and hypotension developing over hours — is the classic presentation of meningococcal meningitis/septicemia. In a complement-inhibited patient, this syndrome can progress to death within hours. The lapse in prophylactic penicillin removed the pharmacological barrier against meningococcal colonization, and vaccination, while reducing risk, does not provide complete protection. Empiric intravenous ceftriaxone must be administered immediately — before lumbar puncture, before culture results, and without delay for any other diagnostic workup. Blood cultures should be drawn en route, and lumbar puncture can follow once antibiotics are initiated and the patient is stabilized.

Option A: Option A is incorrect because obtaining a lumbar puncture before antibiotics introduces a potentially fatal delay in a patient with signs of septic shock and meningococcemia; in a complement-inhibited patient with this presentation, antibiotics precede diagnostic procedures.
Option B: Option B is incorrect because oral amoxicillin and a vaccine booster are wholly inadequate for suspected fulminant meningococcal sepsis; this is a parenteral emergency requiring intravenous bactericidal antibiotics within minutes.
Option C: Option C is incorrect because eculizumab has a half-life of approximately 11 days and discontinuation does not restore complement function acutely; fresh frozen plasma does not reliably or rapidly restore functional terminal complement in a patient on eculizumab; delaying antibiotics to attempt complement restoration would be fatal.
Option E: Option E is incorrect because IVIG is not a treatment for bacterial sepsis and does not contain reliably high-titer bactericidal anti-meningococcal antibodies; standard IVIG formulations are not a substitute for empiric ceftriaxone in suspected meningococcemia.

2. A 44-year-old man received a deceased-donor kidney transplant two years ago and has been maintained on tacrolimus, mycophenolate mofetil, and low-dose prednisone. His current eGFR (estimated glomerular filtration rate) is 51 mL/min/1.73m², and serial biopsies show early calcineurin inhibitor nephrotoxicity with interstitial fibrosis. His transplant nephrologist proposes converting to belatacept-based immunosuppression to halt progressive calcineurin inhibitor-related renal injury. Pre-transplant records confirm the patient was EBV (Epstein-Barr virus)-seronegative at the time of transplantation. He has not been tested for EBV seroconversion since transplant. Which of the following best describes the correct management of this conversion plan?

A) Belatacept is contraindicated in EBV-seronegative transplant recipients per the FDA label; converting this patient to belatacept without establishing current EBV serostatus creates unacceptable risk of post-transplant lymphoproliferative disorder (PTLD) through impaired EBV-specific CTL (cytotoxic T-lymphocyte) surveillance; the conversion should not proceed, and calcineurin inhibitor nephrotoxicity should be managed through dose minimization or switching to a less nephrotoxic immunosuppressive regimen.
B) Conversion to belatacept is appropriate and preferred; the renal protective benefit of eliminating calcineurin inhibitor nephrotoxicity outweighs the PTLD risk in any patient, and EBV serostatus at transplantation is no longer relevant at two years post-transplant because all transplant recipients seroconvert to EBV-positive within 18 months due to immunosuppression-facilitated subclinical viral reactivation.
C) Conversion to belatacept is appropriate provided the patient receives a course of rituximab before the switch; rituximab will deplete circulating B cells and reduce the pool of EBV-infectable cells, creating a window of safety during which belatacept can be initiated without meaningful PTLD risk in an EBV-seronegative patient.
D) Conversion to belatacept is appropriate in this patient because EBV-seronegative status is only a contraindication when belatacept is used as induction therapy; at two years post-transplant, the patient's immune system has equilibrated and belatacept-based maintenance immunosuppression is safe regardless of EBV serostatus.
E) Conversion to belatacept is appropriate if the patient's tacrolimus trough level is currently above 10 ng/mL; high calcineurin inhibitor levels in the context of early fibrosis indicate over-immunosuppression, and switching to belatacept at this stage normalizes the immunosuppressive burden and eliminates the PTLD risk associated with excessive T-cell suppression from over-exposure to tacrolimus.

ANSWER: A

Rationale:

EBV-seronegative status is an FDA-labeled contraindication to belatacept in kidney transplant recipients, and this contraindication applies regardless of time since transplantation. The mechanism is pharmacologically specific: belatacept blocks CD80/CD86-CD28 T-cell co-stimulation, impairing the generation and maintenance of EBV-specific CD8+ cytotoxic T lymphocytes that normally eliminate EBV-infected B cells. An EBV-seronegative recipient who acquires primary EBV infection post-transplant lacks pre-existing EBV-specific CTL memory; if belatacept simultaneously prevents the de novo CTL response required to control primary EBV infection, unchecked EBV-driven B-cell proliferation can progress to PTLD — a potentially fatal lymphoproliferative complication. While calcineurin inhibitor nephrotoxicity is a genuine clinical problem, the correct approach is dose minimization of tacrolimus (targeting lower trough levels of 4 to 6 ng/mL), switching to an alternative such as everolimus (mTOR inhibitor with less nephrotoxicity than tacrolimus at equivalent doses), or careful observation — not conversion to a contraindicated biologic.

Option B: Option B is incorrect because EBV seroconversion is not universal within 18 months in transplant recipients; many EBV-seronegative recipients remain seronegative long-term if they avoid primary EBV exposure; the two-year timeframe does not neutralize the contraindication.
Option C: Option C is incorrect because rituximab-mediated B-cell depletion does not eliminate PTLD risk from belatacept in EBV-seronegative patients; B cells regenerate after rituximab, and the fundamental risk — impaired CTL surveillance of EBV-infected B cells during belatacept therapy — is a T-cell mechanism that rituximab does not address.
Option D: Option D is incorrect because the EBV-seronegative contraindication applies to all phases of belatacept use, including maintenance; the label does not distinguish induction from maintenance phases for this contraindication.
Option E: Option E is incorrect because tacrolimus trough level does not determine whether belatacept is safe in an EBV-seronegative patient; the contraindication is based on immunological mechanism, not on the degree of calcineurin inhibitor exposure.

3. A 58-year-old woman with CIDP (chronic inflammatory demyelinating polyneuropathy) receives monthly IVIG at 1 g/kg over eight hours at a rate of 150 mg/kg/hour. Two days after her most recent infusion, she presents with right calf pain and swelling; duplex ultrasound confirms a proximal deep vein thrombosis (DVT). Her medical history includes obesity (BMI 34 kg/m²), hypertension, and a pulmonary embolism (PE) three years ago. Her neurologist must decide how to manage her CIDP going forward while reducing recurrent thromboembolic risk. Which of the following best identifies the mechanism of this complication and the most appropriate modification to her IVIG regimen?

A) The DVT is caused by IVIG-induced anti-phospholipid antibody formation; pooled donor IgG preparations contain anti-cardiolipin antibodies from donors with subclinical antiphospholipid syndrome, which accumulate over repeated infusions; switching to a single-donor plasma product eliminates the anti-phospholipid antibody burden and resolves the prothrombotic state.
B) The DVT reflects IVIG-induced thrombocytosis; Fc-gamma receptor blockade on splenic macrophages prevents platelet clearance, causing platelet count to rise above 800,000/mcL following each infusion; adding aspirin before each IVIG cycle and targeting a post-infusion platelet count below 400,000/mcL reduces thromboembolic risk while maintaining immunomodulatory efficacy.
C) The DVT is caused by IVIG-induced increases in plasma viscosity and platelet aggregation at high peak IgG concentrations, compounded by this patient's multiple pre-existing cardiovascular risk factors; the appropriate modification is to reduce the infusion rate, divide the dose over more days, ensure adequate pre-infusion hydration, and consider prophylactic anticoagulation given her prior PE and high-risk profile — while continuing IVIG since CIDP requires ongoing immunomodulatory therapy.
D) The DVT is an off-target complement activation effect; high-dose IVIG activates the classical complement pathway through Fc-mediated C1q binding, generating C5a that activates platelets and endothelium; switching to IgA-depleted IVIG eliminates complement-fixing IgG subclasses and resolves the prothrombotic complement activation without changing clinical efficacy.
E) The DVT reflects sucrose-stabilized IVIG formulation nephrotoxicity causing osmotic tubular injury and secondary hypercoagulability; confirming that the current preparation uses sucrose as a stabilizer and switching to a glycine- or maltose-stabilized formulation is the primary intervention needed.

ANSWER: C

Rationale:

IVIG-associated thromboembolic events — including DVT, PE, myocardial infarction, and stroke — represent one of the most clinically important serious adverse effects of high-dose IVIG. The mechanism involves two converging effects of high peak IgG concentrations: increased plasma viscosity from the large protein load, and promotion of platelet aggregation at elevated IgG levels. Together these create a transient prothrombotic state that is most pronounced in the 24 to 72 hours following infusion. This patient has multiple compounding risk factors — obesity, hypertension, prior PE, and age — that significantly amplify her baseline thromboembolic risk. The appropriate response is not to discontinue IVIG (which is the established treatment for CIDP and cannot be replaced in this indication), but to implement risk-reduction strategies: reducing the infusion rate (slowing the peak IgG concentration rise), dividing the dose over more days, ensuring adequate intravenous hydration before and during infusion to reduce viscosity, and seriously considering prophylactic anticoagulation given her history of prior PE and the recurrent nature of the risk.

Option A: Option A is incorrect because IVIG-associated DVT is not caused by anti-phospholipid antibodies passively transferred from donor plasma; pooled IVIG preparations are screened and this is not an established mechanism of IVIG thromboembolism.
Option B: Option B is incorrect because IVIG does not cause thrombocytosis through Fc-gamma receptor blockade; in ITP, Fc-gamma receptor blockade allows platelets to accumulate, but thrombocytosis causing thromboembolism is not an established IVIG adverse effect profile; the mechanism of IVIG thromboembolism is viscosity and platelet aggregation.
Option D: Option D is incorrect because classical complement activation generating C5a-driven platelet activation is not the established mechanism of IVIG thromboembolism; IgA-depleted IVIG addresses anaphylaxis risk in IgA-deficient patients, not thromboembolic risk.
Option E: Option E is incorrect because sucrose-stabilized IVIG causing osmotic nephropathy is a real but distinct IVIG adverse effect; it does not cause hypercoagulability as the mechanism of DVT; modern maltose- or glycine-stabilized formulations are preferred to reduce renal risk, but this is not the primary intervention for thromboembolic prevention in high-risk patients.

4. A 35-year-old man with CLL (chronic lymphocytic leukemia) has been on ibrutinib for eight months with excellent hematological response — his lymphocyte count has normalized and lymphadenopathy has resolved. He now develops palpitations; an ECG shows atrial fibrillation (AF) with rapid ventricular response. He has no prior history of AF or structural heart disease. His cardiologist asks the oncologist whether ibrutinib must be discontinued. Which of the following best describes the pharmacological basis of this complication and the most appropriate oncological management?

A) Ibrutinib must be discontinued permanently; AF caused by BTK (Bruton tyrosine kinase) inhibition is a class effect that is irreversible once established, and continuing any BTK inhibitor after AF onset significantly increases the risk of progression to ventricular fibrillation through the same off-target kinase inhibition pathway that triggered the initial arrhythmia.
B) Ibrutinib-associated AF results from off-target inhibition of ITK (interleukin-2-inducible T-cell kinase) and EGFR (epidermal growth factor receptor), which are expressed in cardiac conduction tissue and disrupt atrial electrophysiology; switching to acalabrutinib or zanubrutinib — second-generation covalent BTK inhibitors with greater BTK selectivity and substantially lower off-target kinase inhibition — is the preferred strategy to maintain CLL disease control while reducing ongoing AF risk.
C) Ibrutinib-associated AF is caused by on-target BTK inhibition in sinoatrial nodal cells where BTK regulates the HCN4 (hyperpolarization-activated cyclic nucleotide-gated channel 4) pacemaker current; because all covalent BTK inhibitors share this on-target cardiac mechanism, switching to acalabrutinib offers no arrhythmia benefit and ibrutinib should simply be dose-reduced by 50%.
D) Ibrutinib must be interrupted for at least 30 days to allow cardiac recovery before any BTK inhibitor can be restarted; the required washout period reflects the time needed for covalently inhibited BTK molecules in cardiac tissue to be replaced by newly synthesized BTK, after which acalabrutinib can be safely initiated at a reduced starting dose.
E) Ibrutinib-associated AF is caused by ibrutinib's boron-containing functional group forming adducts with cardiac ion channel proteins in atrial myocytes; because acalabrutinib also contains a boron-containing warhead, switching does not reduce AF risk; the appropriate management is ibrutinib dose reduction to 280 mg daily combined with rate-control therapy.

ANSWER: B

Rationale:

Ibrutinib-associated atrial fibrillation occurs in approximately 10 to 16% of patients and is one of its most clinically significant adverse effects. The mechanism is off-target kinase inhibition: ibrutinib covalently inhibits multiple kinases beyond BTK that share the cysteine-481 binding motif, most importantly ITK (IL-2-inducible T-cell kinase) and EGFR (epidermal growth factor receptor), both of which are expressed in cardiac tissue and are involved in atrial electrophysiology and conduction. This off-target inhibition disrupts normal atrial electrical signaling and promotes AF. Second-generation covalent BTK inhibitors — acalabrutinib and zanubrutinib — were engineered with structural modifications that improve BTK selectivity and minimize off-target kinase inhibition; both demonstrate substantially lower AF rates in clinical trials compared to ibrutinib. Switching to acalabrutinib or zanubrutinib maintains CLL disease control (both are highly effective for CLL) while reducing the ongoing AF-promoting pharmacological mechanism. This patient is young with excellent disease response, making disease control a high priority; stopping BTK inhibitor therapy entirely for a manageable adverse effect is not the preferred approach when a safer alternative within class exists.

Option A: Option A is incorrect because AF from BTK inhibitors is not irreversible or a harbinger of ventricular fibrillation; it is a recognized, manageable adverse effect; switching to a more selective BTK inhibitor is the established clinical strategy rather than permanent class discontinuation.
Option C: Option C is incorrect because ibrutinib-associated AF is caused by off-target kinase inhibition (not on-target BTK inhibition in sinoatrial nodal cells), and acalabrutinib does have a substantially lower AF rate; dose reduction of ibrutinib does not specifically address the off-target kinase contribution.
Option D: Option D is incorrect because a mandatory 30-day washout before switching BTK inhibitors is not established in clinical guidelines; ibrutinib is an irreversible inhibitor but its plasma half-life is short (approximately 4 to 6 hours), and newly synthesized BTK protein replenishes rapidly; waiting 30 days has no pharmacological rationale.
Option E: Option E is incorrect because ibrutinib does not contain a boron-containing functional group — that is the chemical feature of bortezomib (a proteasome inhibitor); ibrutinib is an acrylamide-based covalent kinase inhibitor; acalabrutinib is also acrylamide-based and does have a substantially lower AF rate.

5. A 49-year-old woman with refractory generalized myasthenia gravis (MG) has been receiving daratumumab infusions for four months as part of a clinical protocol for antibody-mediated autoimmune disease. She is scheduled for elective right total knee arthroplasty next week. Her orthopedic surgeon orders routine pre-operative type and screen. The blood bank calls the surgeon to report that the antibody screen is showing pan-reactive positive results on all reagent cells and that a standard crossmatch cannot be interpreted. The surgeon is unfamiliar with this finding and asks for an explanation. Which of the following best explains the blood bank finding and the required pre-operative action?

A) The pan-reactive screen reflects warm autoimmune hemolytic anemia induced by daratumumab; the drug has stimulated autoreactive B-cell clones through NK-cell depletion, generating anti-erythrocyte antibodies that coat all donor cells in the crossmatch; the surgical team should postpone elective surgery until hemolysis is controlled and direct antiglobulin test becomes negative.
B) The pan-reactive screen indicates the patient has developed multiple red cell alloantibodies from prior transfusions; this is unrelated to daratumumab and reflects her underlying immunological dysregulation from myasthenia gravis; the blood bank should perform an extended alloantibody panel using enzyme-treated cells and can release blood within 24 hours.
C) The pan-reactive screen is caused by daratumumab's IgG1 Fc region activating complement on all reagent red cells during the indirect antiglobulin test, producing non-specific C3d deposition detectable by the Coombs reagent; using low-ionic-strength saline (LISS) enhancement medium instead of albumin will neutralize the complement activation and restore interpretable crossmatch results.
D) The pan-reactive screen reflects HLA antibody sensitization from prior surgeries or pregnancy; daratumumab promotes HLA antibody formation by depleting regulatory T cells that normally suppress alloimmune responses; the blood bank must use HLA-matched red cells and cannot use standard crossmatch-incompatible units under any circumstances.
E) Daratumumab binds CD38 on the surface of normal human erythrocytes; daratumumab present in the patient's plasma coats all CD38-positive reagent cells during antibody screening and crossmatch testing, and the bound drug is detected by the anti-human IgG Coombs reagent, producing a pan-reactive false-positive result; the blood bank must be notified that the patient is on daratumumab before blood is needed, and specialized pre-transfusion testing using DTT (dithiothreitol)-treated or CD38-null reagent cells, or molecular blood group genotyping, must be arranged in advance of surgery.

ANSWER: E

Rationale:

This vignette illustrates the critical pre-surgical planning implication of daratumumab's CD38-binding mechanism. CD38 is expressed at low but functionally significant levels on normal human erythrocytes. When daratumumab is circulating in the patient's plasma at therapeutic concentrations, it binds CD38 on every red cell surface it encounters in the blood bank — including the reagent panel cells used for antibody identification and the donor cells used for crossmatch. The anti-human IgG Coombs reagent then detects daratumumab (a human IgG1 antibody) bound to these CD38-positive reagent cells, generating a positive signal on all cells tested — a pan-reactive pattern that cannot be distinguished from multiple alloantibodies by standard serological methods. This pan-reactivity masks the detection of any true alloantibodies that would indicate genuine incompatibility. The key clinical lesson is proactive communication: the treating physician and blood bank must be informed that a patient is on daratumumab before blood products are anticipated, and specialized testing must be arranged in advance — not as an emergency response when surgery is already scheduled. Validated methods include dithiothreitol (DTT) treatment of reagent cells (which cleaves CD38 from the erythrocyte surface, eliminating daratumumab binding, though DTT also destroys Kell antigens) or molecular blood group genotyping to identify antigen-matched compatible units without serological testing.

Option A: Option A is incorrect because daratumumab-induced warm autoimmune hemolytic anemia is an uncommon recognized adverse effect but is not the cause of this pan-reactive screening pattern; the pan-reactivity is a laboratory interference phenomenon caused by daratumumab binding CD38 on reagent cells, not by newly formed autoantibodies.
Option B: Option B is incorrect because the pan-reactive pattern is distinctly not consistent with typical alloantibody sensitization (which would produce a selective pattern rather than pan-reactivity on all cells); and the finding is directly attributable to daratumumab.
Option C: Option C is incorrect because daratumumab does not activate complement non-specifically on reagent red cells through its Fc region; the interference mechanism is specific CD38 binding, not Fc-mediated complement activation; LISS substitution does not resolve CD38-based interference.
Option D: Option D is incorrect because daratumumab does not cause HLA sensitization through regulatory T-cell depletion; HLA antibodies produce a different serological pattern; and the blood bank instruction to withhold all incompatible blood indefinitely would be clinically dangerous in surgical emergencies.

6. A 31-year-old man with PNH has been on eculizumab for three years. His LDH (lactate dehydrogenase) has been consistently normal, he has had no hemoglobinuria, and there have been no thrombotic events — indicating good control of intravascular hemolysis. Despite this, his hemoglobin has never risen above 8.5 g/dL and remains at 8.1 g/dL, with a reticulocyte count of 280 × 10⁹/L (elevated) and indirect bilirubin of 42 µmol/L (elevated), consistent with ongoing hemolysis. His hematologist discontinues eculizumab and starts iptacopan monotherapy. Three months later, his hemoglobin is 12.8 g/dL, reticulocyte count has normalized, and indirect bilirubin is normal. Which of the following best explains why iptacopan produced a hemoglobin response that eculizumab could not?

A) Iptacopan has greater C5 binding affinity than eculizumab and achieves more complete terminal complement inhibition, eliminating residual intravascular hemolysis that persisted due to subtherapeutic eculizumab trough levels in this patient's dosing interval.
B) Iptacopan blocks MAC formation through a different binding site on C5 than eculizumab, overcoming the C5 polymorphism (p.Arg885His) that renders eculizumab ineffective in a subset of East Asian patients, allowing terminal complement inhibition to be achieved for the first time in this patient.
C) Iptacopan adds a C5aR1-blocking effect to terminal complement inhibition, preventing C5a-mediated macrophage activation in the reticuloendothelial system; the persistent anemia on eculizumab was driven by C5a-mediated splenic macrophage activation rather than C3b opsonization, and iptacopan's dual mechanism addresses both.
D) Eculizumab blocks MAC formation but does not affect C3 cleavage; C3b continued to deposit on GPI-deficient PNH erythrocytes, opsonizing them for phagocytosis by Kupffer cells and splenic macrophages — a process called extravascular hemolysis — which maintained the anemia despite normal LDH. Iptacopan inhibits Factor B and blocks alternative pathway C3 convertase assembly, preventing C3b deposition and thereby eliminating both intravascular hemolysis (downstream MAC blockade) and extravascular hemolysis (preventing C3b opsonization), producing the full hemoglobin recovery.
E) Eculizumab requires intravenous infusion every two weeks, creating trough periods of insufficient C5 blockade during which MAC formation resumes; iptacopan's continuous oral daily dosing maintains steady-state Factor B inhibition without dosing gaps, eliminating the trough-related hemolysis that was responsible for the persistent anemia on eculizumab.

ANSWER: D

Rationale:

This vignette presents the characteristic clinical signature of extravascular hemolysis in a PNH patient on anti-C5 therapy — normal LDH (no intravascular lysis), elevated indirect bilirubin and reticulocyte count (ongoing red cell destruction and marrow compensation), and persistent anemia despite good disease control by conventional anti-C5 endpoints. The pharmacological explanation is fundamental to understanding why anti-C5 therapy has a ceiling of efficacy. Eculizumab blocks C5 cleavage, preventing MAC-mediated intravascular lysis — hence the normal LDH. However, C3 activation and C3b deposition are entirely upstream of C5 and unaffected by eculizumab. C3b continues to opsonize GPI-deficient PNH erythrocytes (which lack CD55 and CD59), marking them for phagocytic destruction by Kupffer cells in the liver and splenic macrophages — extravascular hemolysis. This accounts for approximately 30% of PNH patients on anti-C5 therapy who have residual clinically significant anemia. Iptacopan inhibits Factor B, the serine protease component of the alternative pathway C3 convertase (C3bBb); by blocking this step, iptacopan prevents C3b amplification via the alternative pathway, substantially reducing C3b deposition on PNH erythrocytes and thereby eliminating both the intravascular hemolysis (by also blocking the pathway that generates C5 convertase) and extravascular hemolysis (by preventing C3b opsonization). The dramatic hemoglobin recovery from 8.1 to 12.8 g/dL reflects the elimination of the extravascular hemolysis that eculizumab could not address.

Option A: Option A is incorrect because the problem is not subtherapeutic eculizumab dosing — his LDH is consistently normal, confirming adequate MAC blockade; the residual hemolysis is mechanistically upstream of C5, not a dose failure.
Option B: Option B is incorrect because the C5 polymorphism (p.Arg885His) that reduces eculizumab binding in some East Asian patients is a real pharmacogenomic issue, but iptacopan does not work by binding C5 at all — it inhibits Factor B in the alternative pathway; this option misidentifies iptacopan's mechanism.
Option C: Option C is incorrect because iptacopan does not block C5aR1; C5aR1 antagonism is the mechanism of avacopan; the persistent anemia on eculizumab is caused by C3b opsonization and extravascular hemolysis, not by C5a-mediated macrophage activation per se.
Option E: Option E is incorrect because eculizumab trough periods do not cause clinically significant breakthrough hemolysis at standard dosing intervals in most patients; the persistent anemia in this patient is due to ongoing extravascular hemolysis that anti-C5 therapy structurally cannot prevent, not to dosing gaps.

7. A 67-year-old woman with rheumatoid arthritis maintained on tocilizumab develops fever of 38.9°C, productive cough with purulent sputum, and right-sided pleuritic chest pain. Her CBC (complete blood count) shows a WBC of 16,400/mcL with 91% neutrophils. CRP is 7 mg/L (laboratory reference <10 mg/L, reported as within normal limits). Procalcitonin is 3.6 ng/mL (elevated; laboratory reference <0.25 ng/mL). Chest X-ray shows a right lower lobe infiltrate. The medical intern reviews the results and notes the normal CRP, concluding that the inflammatory markers do not support a bacterial infection and recommending observation with repeat imaging in 48 hours. The attending physician immediately corrects this interpretation. Which of the following best identifies the pharmacological error in the intern's reasoning and states the correct clinical conclusion?

A) The intern's error is applying standard CRP interpretation to a patient on tocilizumab; tocilizumab blocks IL-6 receptor signaling, which is the primary driver of hepatic CRP synthesis, suppressing CRP production even during active bacterial infection; the normal CRP is pharmacologically caused and does not reflect the true inflammatory state; the elevated procalcitonin — produced through IL-6-independent pathways — correctly identifies bacterial infection, and empiric antibiotics are indicated immediately.
B) The intern's error is over-relying on a single biomarker; CRP below 10 mg/L correctly excludes severe bacterial infection in immunocompetent patients, but tocilizumab-treated patients require a CRP threshold of 50 mg/L to achieve equivalent negative predictive value due to baseline elevation of acute-phase reactants from underlying RA; the normal CRP at this threshold still indicates a viral rather than bacterial etiology.
C) The intern's error is not recognizing that tocilizumab causes a neutrophilic shift by upregulating G-CSF (granulocyte colony-stimulating factor) production, making leukocytosis an unreliable marker of bacterial infection; the procalcitonin elevation is also non-specific in tocilizumab-treated patients because IL-6R blockade upregulates PCT production basally; blood cultures and bronchoscopy are required before any antibiotic decision can be made.
D) The intern's error is not ordering an ESR (erythrocyte sedimentation rate); ESR is unaffected by tocilizumab because it reflects fibrinogen and immunoglobulin levels rather than IL-6-dependent acute-phase reactants; an elevated ESR would confirm bacterial infection and justify antibiotic initiation, while a normal ESR at this presentation would support the intern's watchful waiting approach.
E) The intern's error is using procalcitonin rather than CRP as the primary biomarker; in rheumatoid arthritis patients, procalcitonin is constitutively elevated due to synovial inflammation producing bacterial-pattern cytokine signals, making it falsely positive for bacterial infection; the normal CRP is the more reliable marker and correctly indicates that this is a RA flare with pulmonary involvement rather than bacterial pneumonia.

ANSWER: A

Rationale:

This vignette directly tests the ability to apply the pharmacological mechanism of IL-6R blockade to a critical clinical decision. Tocilizumab blocks the IL-6 receptor (both soluble and membrane-bound forms), preventing IL-6 from signaling to hepatocytes via the JAK1-STAT3 pathway. IL-6 is the principal cytokine driving hepatic synthesis of CRP (C-reactive protein) and other acute-phase reactants; its blockade produces pharmacological suppression of CRP synthesis that is independent of the actual inflammatory or infectious stimulus. A patient on tocilizumab will have a consistently low or normal CRP regardless of whether they have active RA, bacterial pneumonia, or sepsis — making CRP a dangerously unreliable biomarker in this population. The intern's reasoning — concluding that normal CRP argues against bacterial infection — is a pharmacologically grounded error that could result in withholding antibiotics from a patient with bacterial pneumonia. Procalcitonin (PCT) is produced by parenchymal cells throughout the body in response to bacterial endotoxin (lipopolysaccharide) and to IL-1beta and TNF, which are upstream of and independent of IL-6 signaling; PCT production is not suppressed by IL-6R blockade and rises normally during bacterial infection. The elevated PCT of 3.6 ng/mL combined with fever, purulent cough, neutrophilia, and a lobar infiltrate provides strong evidence for bacterial pneumonia requiring immediate empiric antibiotic therapy.

Option B: Option B is incorrect because there is no validated alternative CRP threshold of 50 mg/L for tocilizumab-treated patients; CRP is pharmacologically suppressed at the level of synthesis and cannot be re-calibrated with a higher threshold; the intern's error is categorical, not a matter of threshold adjustment.
Option C: Option C is incorrect because tocilizumab does not cause G-CSF-driven neutrophilic pseudoshift or basally elevated PCT; leukocytosis on CBC is not suppressed by IL-6R blockade and remains informative; PCT is the preferred infection biomarker precisely because it is reliably elevated only during bacterial infection regardless of IL-6R blockade.
Option D: Option D is incorrect because while ESR is relatively preserved in tocilizumab-treated patients (as it reflects fibrinogen and immunoglobulin concentrations), it is non-specific and a normal ESR would not safely exclude bacterial pneumonia; observation without antibiotics in this presentation is incorrect regardless of ESR result.
Option E: Option E is incorrect because procalcitonin is not constitutively elevated in rheumatoid arthritis; PCT is specifically elevated during bacterial infection and not during autoimmune inflammation; it is the preferred biomarker in this population precisely because it is IL-6-independent and not falsely elevated by RA.

8. A 52-year-old man with aHUS (atypical hemolytic uremic syndrome) caused by a Factor H mutation has been on eculizumab for four years with stable renal function (eGFR 58 mL/min/1.73m²) and no TMA (thrombotic microangiopathy) recurrence. He is scheduled for elective right total hip arthroplasty. The orthopedic surgery team asks the rheumatology/nephrology team whether any complement-specific perioperative precautions are required beyond standard antibiotic surgical prophylaxis. Which of the following correctly identifies the mandatory complement-related perioperative precautions for this patient?

A) Eculizumab should be discontinued two weeks before surgery to allow partial recovery of terminal complement function, which reduces the risk of post-operative bacterial infection from encapsulated organisms; it can be restarted once the surgical wound is fully closed and drain output is minimal, typically at post-operative day five to seven.
B) No complement-specific precautions are required beyond standard surgical antibiotic prophylaxis; the meningococcal vaccination given before eculizumab initiation provides durable lifelong protection against meningococcal disease, and the risk of complement-related infection is negligible in a vaccinated patient undergoing an elective procedure with appropriate perioperative antibiotics.
C) Eculizumab must be continued without interruption through the perioperative period to prevent TMA recurrence — aHUS can be triggered by surgical stress, and discontinuing eculizumab perioperatively risks fulminant TMA recurrence with acute kidney injury; additionally, meningococcal vaccination status must be confirmed current and prophylactic antibiotics covering encapsulated organisms should be continued throughout the perioperative period given the sustained meningococcal vulnerability from ongoing MAC blockade.
D) Eculizumab should be administered as a supplemental extra dose on the day of surgery rather than maintaining the standard dosing schedule; the surgical inflammatory response transiently upregulates complement activity, requiring a higher eculizumab concentration to maintain adequate C5 blockade during the perioperative window; standard dosing may be inadequate during this high-demand period.
E) The only complement-specific precaution required is to schedule surgery at least 14 days after the most recent eculizumab infusion to take advantage of trough-period partial complement recovery, which reduces post-operative infection risk from complement inhibition while maintaining adequate residual drug levels to prevent TMA recurrence during the operative period.

ANSWER: C

Rationale:

This vignette requires applying the pharmacological imperatives of anti-C5 therapy to surgical planning. Two distinct complement-related precautions are mandatory for this patient. First, eculizumab must not be interrupted perioperatively in a patient with aHUS due to Factor H mutation. aHUS is caused by uncontrolled alternative pathway activation in the renal microvasculature, and this patient's disease is pharmacologically controlled — not cured — by eculizumab. Surgical stress and the inflammatory response to surgery are recognized triggers of complement activation and TMA recurrence; discontinuing eculizumab perioperatively removes the pharmacological protection against a TMA episode that could cause acute renal failure in a patient who already has reduced baseline eGFR from prior disease. Second, eculizumab's ongoing mechanism — blocking MAC formation — creates persistent vulnerability to meningococcal and other encapsulated bacterial infections that does not diminish during the surgical period. Prophylactic antibiotic coverage covering encapsulated organisms (typically penicillin V or amoxicillin) should be confirmed and continued; vaccination status should be reviewed; and the surgical and anesthesia teams must understand that any post-operative fever in this patient warrants aggressive evaluation and empiric antibiotic coverage given the impaired terminal complement bactericidal defense.

Option A: Option A is incorrect because discontinuing eculizumab before surgery is directly contraindicated in aHUS — TMA recurrence is a well-documented risk of treatment interruption, particularly during inflammatory triggers such as surgery; withholding eculizumab to "restore complement function" would endanger the patient's kidneys.
Option B: Option B is incorrect because meningococcal vaccination does not provide lifelong durable protection sufficient to eliminate complement infection precautions; vaccination reduces but does not eliminate meningococcal risk, and breakthrough disease occurs in vaccinated eculizumab-treated patients; ongoing prophylactic antibiotics are part of the standard of care.
Option D: Option D is incorrect because supplemental extra-dose eculizumab on the day of surgery is not a standard perioperative protocol; standard dosing schedules are designed to maintain adequate C5 blockade, and the established management is maintaining the standard regimen, not adding extra doses without clinical indication.
Option E: Option E is incorrect because scheduling surgery at trough periods to allow partial complement recovery is not recommended and would be clinically counterproductive in aHUS — any reduction in eculizumab coverage during a surgical inflammatory trigger increases TMA recurrence risk.

9. A 38-year-old woman with SLE (systemic lupus erythematosus) has persistently active skin rash, photosensitivity, arthritis, and fatigue despite hydroxychloroquine 400 mg/day and low-dose prednisone 7.5 mg/day. Her complement C3 and C4 are mildly low, anti-dsDNA titer is elevated at 1:320, and her peripheral blood interferon gene signature (ISG) score — a measure of type I interferon pathway activation determined by gene expression profiling — returns as strongly positive (high). Her rheumatologist initiates anifrolumab rather than belimumab and explains to the patient that a specific laboratory result guided this selection. Which of the following best explains why the ISG score directed the rheumatologist toward anifrolumab over belimumab in this patient?

A) The high ISG score indicates elevated BAFF (B-cell activating factor) production driven by type I interferon signaling; because anifrolumab blocks IFNAR1 (type I interferon receptor 1) upstream of BAFF induction, it simultaneously reduces both the interferon pathway and the BAFF-mediated B-cell hyperactivation that belimumab would address only downstream; anifrolumab therefore provides more complete immunosuppression at a single molecular target.
B) A high ISG score identifies active type I interferon pathway signaling as the dominant immunopathological driver of this patient's SLE; anifrolumab blocks IFNAR1 and suppresses type I interferon-driven gene expression, inflammation, and autoantibody-promoting effects; clinical trial data demonstrate that SLE patients with a high ISG score have greater clinical response to anifrolumab than ISG-negative patients, making it the biomarker-guided first choice; belimumab targets BAFF through an interferon-independent pathway and would be preferred if the ISG score were negative or if B-cell-predominant pathology were the primary driver.
C) The high ISG score indicates that the patient's SLE is being driven by type III interferon (interferon-lambda) signaling rather than type I interferons; anifrolumab blocks IFNAR1 which is shared between type I and type III interferon receptors, making it effective in both ISG-high and ISG-low patients; belimumab has no activity against interferon-lambda and is therefore the inferior choice in patients with high ISG scores.
D) The high ISG score predicts a high likelihood of belimumab resistance because BAFF receptor downregulation occurs as a secondary effect of sustained type I interferon signaling; patients with high ISG scores have low surface BAFF receptor density on B cells, making them pharmacodynamically unresponsive to belimumab's BAFF-neutralizing mechanism; anifrolumab is used first in this setting to restore BAFF receptor expression before belimumab is subsequently added.
E) The ISG score does not directly inform the choice between anifrolumab and belimumab; both agents are equally effective regardless of ISG status in active SLE; the rheumatologist chose anifrolumab because this patient's elevated anti-dsDNA and low complement indicate active immune complex-mediated nephritis, and anifrolumab is specifically approved for lupus nephritis while belimumab is restricted to non-renal SLE manifestations.

ANSWER: B

Rationale:

This vignette illustrates the precision immunopharmacology principle of biomarker-guided biologic selection in SLE. The interferon gene signature (ISG) score reflects the level of type I interferon pathway activation in peripheral blood cells and is a validated predictive biomarker for anifrolumab response. Type I interferons (principally interferon-alpha and interferon-beta) drive multiple SLE pathological mechanisms — promoting dendritic cell maturation, B-cell class-switching and autoantibody production, T-cell activation, and upregulation of inflammatory mediators. Approximately 60 to 80% of SLE patients have a positive (high) ISG score, indicating active type I interferon pathway signaling; this patient's strongly positive ISG score places her in the subgroup with the greatest predicted response to anifrolumab, which blocks IFNAR1 (the shared receptor for type I interferons) and thereby suppresses this entire downstream signaling network. Clinical trial data from the TULIP-1 and TULIP-2 trials confirm that ISG-high patients achieve greater BICLA (BILAG-based Composite Lupus Assessment) response rates to anifrolumab than ISG-low patients. Belimumab targets BAFF — a B-cell survival cytokine — through a mechanism entirely independent of the interferon pathway; it would be the preferred biologic in an ISG-negative patient whose disease is driven predominantly by B-cell hyperactivation and BAFF signaling.

Option A: Option A is incorrect because anifrolumab does not block BAFF; BAFF is produced by multiple cell types and its production is not directly upstream of IFNAR1 signaling in a simple linear pathway; the framing of anifrolumab as simultaneously targeting both pathways through a single upstream block misrepresents the pharmacology.
Option C: Option C is incorrect because type III interferons (interferon-lambda) signal through a different receptor complex (IFNLR1/IL-10R2) that is distinct from IFNAR1; anifrolumab specifically blocks IFNAR1 and does not block the type III interferon receptor; the ISG score primarily reflects type I interferon activation.
Option D: Option D is incorrect because BAFF receptor downregulation causing belimumab resistance in ISG-high patients is not an established mechanism; belimumab efficacy does not depend on ISG score; the pharmacological relationship described is fabricated.
Option E: Option E is incorrect because the ISG score does directly inform biologic selection between anifrolumab and belimumab as described; and the characterization of the patient as having lupus nephritis is not established in the vignette (low complement and elevated anti-dsDNA raise nephritis risk but are not diagnostic); both anifrolumab and belimumab have been studied in SLE with and without nephritis.

10. A 63-year-old man with relapsed multiple myeloma has completed six cycles of bortezomib and has developed grade 2 peripheral neuropathy (moderate sensory loss, limiting instrumental activities of daily living). His oncologist plans to switch to a next-generation proteasome inhibitor. Echocardiogram obtained as part of his pre-treatment workup shows a left ventricular ejection fraction (EF) of 40% — new compared to a normal echo one year ago. Which of the following best identifies the correct proteasome inhibitor selection for this patient given both his neuropathy and his newly discovered cardiac dysfunction?

A) Carfilzomib is preferred because it is an irreversible proteasome inhibitor with lower neuropathy rates than bortezomib, and its cardiovascular effects are limited to transient blood pressure elevation that resolves with dose modification; the EF of 40% does not contraindicate carfilzomib and does not require specialist evaluation before initiation.
B) Bortezomib should be continued at a reduced dose of 1.0 mg/m² (down from the standard 1.3 mg/m²) with a switch from twice-weekly to once-weekly scheduling; dose reduction reliably reverses existing peripheral neuropathy within two cycles and the oncological efficacy of reduced-dose bortezomib is equivalent to full-dose carfilzomib or ixazomib in relapsed disease.
C) Carfilzomib is preferred over ixazomib because it is intravenous and provides more reliable drug delivery than the oral route in a patient with potential gastrointestinal absorption variability from his underlying myeloma; the EF of 40% is a mild reduction that is common in myeloma patients from immunoglobulin light chain cardiotoxicity and does not influence proteasome inhibitor selection.
D) Neither carfilzomib nor ixazomib should be used; the combination of peripheral neuropathy and reduced ejection fraction indicates systemic AL (light chain) amyloidosis rather than primary myeloma toxicity, and both agents are contraindicated in amyloid cardiomyopathy; the patient requires cardiac biopsy confirmation before any further proteasome inhibitor therapy.
E) Carfilzomib is associated with significant cardiovascular toxicity — including hypertension, heart failure, and cardiomyopathy — that limits its use in patients with reduced ejection fraction or pre-existing cardiac dysfunction; ixazomib, an oral proteasome inhibitor with a lower cardiovascular toxicity profile, is the more appropriate choice for this patient, offering reduced neuropathy risk compared to bortezomib and avoiding the cardiac risk of carfilzomib in the context of a newly reduced EF.

ANSWER: E

Rationale:

This vignette requires simultaneously applying two adverse effect profiles — bortezomib neuropathy and carfilzomib cardiovascular toxicity — to identify the correct agent for a patient with contraindications to both the continuing agent and the first alternative considered. Bortezomib causes dose-limiting peripheral neuropathy in approximately 30 to 40% of patients; this patient's grade 2 neuropathy justifies switching. Carfilzomib is an irreversible epoxyketone proteasome inhibitor with a substantially lower neuropathy rate than bortezomib (approximately 17%), making it a reasonable neuropathy-sparing switch. However, carfilzomib has a distinct and clinically significant cardiovascular toxicity profile: hypertension (occurring in up to 40% of patients), cardiac failure, cardiomyopathy, cardiac arrest, and pulmonary hypertension have been reported; patients with pre-existing cardiac dysfunction including reduced EF are at substantially elevated risk and carfilzomib is generally avoided or used with extreme caution in this population. This patient's newly discovered EF of 40% — a meaningful reduction from his prior normal echo — raises concern for carfilzomib-associated or myeloma-related cardiac injury and represents a relative-to-absolute contraindication to carfilzomib initiation. Ixazomib is an oral boron-containing proteasome inhibitor (first oral agent approved in its class) with a lower neuropathy rate than bortezomib and without the cardiovascular toxicity profile of carfilzomib, making it the appropriate selection when both neuropathy avoidance and cardiac safety are required. Its principal toxicities are gastrointestinal (nausea, diarrhea) and cutaneous (rash).

Option A: Option A is incorrect because carfilzomib cardiovascular toxicity is not limited to transient blood pressure elevation; cardiomyopathy, heart failure, and cardiac arrest are serious documented toxicities; an EF of 40% does represent a contraindication-level concern and requires cardiology evaluation before any carfilzomib initiation.
Option B: Option B is incorrect because dose-reduced bortezomib does not reliably reverse established grade 2 neuropathy within two cycles; neuropathy from bortezomib is often cumulative and may be irreversible; continuing the neurotoxic agent at any dose is not the preferred strategy when alternative agents exist.
Option C: Option C is incorrect because carfilzomib's cardiovascular toxicity is not limited to immunoglobulin light chain cardiotoxicity and is not negligible in reduced EF; intravenous versus oral route reliability is not the primary selection criterion here.
Option D: Option D is incorrect because the clinical picture presented — bortezomib neuropathy after six cycles of chemotherapy for known myeloma — does not require ruling out amyloidosis before switching proteasome inhibitor; while AL amyloidosis is a real diagnostic consideration in myeloma patients with cardiac findings, refusing to switch proteasome inhibitors pending biopsy confirmation is not the standard approach in this scenario.

11. A 46-year-old woman with severe pemphigus vulgaris (PV) has received two courses of rituximab (1,000 mg IV at 0 and 2 weeks, repeated at 6 months) with confirmed B-cell depletion on each occasion (CD19+ B cells <0.5% on flow cytometry). Despite this, she has persistent extensive blistering, and her anti-desmoglein 3 IgG titer by ELISA (enzyme-linked immunosorbent assay) has not declined significantly after either rituximab course. Her dermatologist adds subcutaneous bortezomib to her regimen. Which of the following best explains the mechanism by which bortezomib is expected to reduce her anti-desmoglein 3 titers, and what serological response should the dermatologist anticipate?

A) Bortezomib will deplete circulating B cells that escaped rituximab-mediated depletion by upregulating anti-apoptotic BCL-2 (B-cell lymphoma 2) proteins; proteasome inhibition by bortezomib degrades BCL-2 through the ubiquitin-proteasome pathway, re-sensitizing rituximab-resistant B cells to apoptosis and eliminating the residual anti-desmoglein B-cell clone responsible for ongoing antibody production.
B) Bortezomib will reduce anti-desmoglein 3 titers by inhibiting the NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in circulating plasmablasts, which depends on proteasome-mediated degradation of IkappaB (inhibitor of kappa B) for NF-kappaB activation; blocking this step prevents plasmablast survival and reduces antibody secretion within 48 to 72 hours of the first dose.
C) Bortezomib will reduce anti-desmoglein 3 titers by activating the classical complement pathway on plasma cells through its dipeptide boronic acid scaffold, opsonizing long-lived plasma cells for MAC-mediated lysis; this mechanism is independent of the unfolded protein response and targets plasma cells specifically in the bone marrow rather than in peripheral blood.
D) Bortezomib inhibits the 26S proteasome, blocking degradation of misfolded immunoglobulin chains in plasma cells and triggering lethal unfolded protein response (UPR) overload; long-lived plasma cells producing anti-desmoglein 3 antibodies are selectively vulnerable because their extraordinary immunoglobulin secretion rate generates protein folding stress that the proteasome normally manages; bortezomib kills these cells, and the dermatologist should expect a gradual reduction in anti-desmoglein 3 titers over weeks to months as the plasma cell pool is depleted, correlating with clinical skin improvement.
E) Bortezomib will reduce anti-desmoglein 3 titers by blocking FcRn-mediated IgG recycling in plasma cells; proteasome inhibition prevents FcRn from being recycled back to the plasma cell surface after IgG transcytosis, causing newly synthesized anti-desmoglein 3 IgG to be retained intracellularly and degraded before secretion, reducing serum antibody levels without depleting the plasma cell population itself.

ANSWER: D

Rationale:

This vignette requires applying the mechanism of plasma cell vulnerability to proteasome inhibition in the specific clinical context of rituximab-refractory pemphigus vulgaris. The confirmed B-cell depletion on each rituximab course, combined with persistent high anti-desmoglein 3 titers, is the classic pattern of long-lived plasma cell-maintained autoantibody production. Long-lived plasma cells are terminally differentiated cells that have lost CD20 expression and reside in bone marrow survival niches — pharmacologically invisible to rituximab. They continue producing anti-desmoglein 3 IgG at high rates regardless of circulating B-cell levels. Bortezomib exploits the fundamental metabolic vulnerability of plasma cells: to sustain their exceptionally high immunoglobulin synthesis rate (a terminally differentiated plasma cell can secrete on the order of thousands of immunoglobulin molecules per minute), these cells generate a proportionally high burden of misfolded or unassembled immunoglobulin chains that must be cleared by the unfolded protein response (UPR) and the 26S proteasome. When bortezomib inhibits the beta5 catalytic subunit of the 20S proteasome, misfolded immunoglobulin accumulates, the UPR becomes overwhelmed, and the terminal UPR pathways (IRE1, PERK, ATF6) drive plasma cell apoptosis. Because rituximab has already depleted the precursor B-cell pool, new plasma cell generation from B-cell maturation is suppressed; bortezomib targets the existing long-lived plasma cell reservoir. The serological response is gradual — anti-desmoglein 3 titers decline over weeks to months as plasma cells die and are not replaced, and clinical skin improvement follows the antibody reduction.

Option A: Option A is incorrect because bortezomib does not target BCL-2 directly through the proteasome pathway in a manner that restores rituximab sensitivity; rituximab resistance in PV is not due to BCL-2 upregulation in circulating B cells but to long-lived plasma cells lacking CD20.
Option B: Option B is incorrect because while proteasome inhibition does affect NF-kappaB signaling (IkappaB is normally degraded by the proteasome to release NF-kappaB), the primary mechanism of plasma cell killing by bortezomib is UPR overload from proteasome inhibition in high-immunoglobulin-secreting cells, not NF-kappaB suppression in plasmablasts; and the timescale of 48 to 72 hours for anti-desmoglein titer reduction is far too rapid for a plasma cell depletion mechanism.
Option C: Option C is incorrect because bortezomib does not activate complement through its boronic acid scaffold; complement activation on plasma cells is a recognized mechanism of daratumumab (anti-CD38), not bortezomib; bortezomib's mechanism is proteasome inhibition and UPR-driven apoptosis.
Option E: Option E is incorrect because FcRn-mediated IgG recycling in plasma cells is not the mechanism of bortezomib action; FcRn saturation by exogenous IgG is the mechanism of IVIG-mediated autoantibody catabolism; bortezomib does not interact with FcRn.